The three major authoritative institutions jointly launched the "Diabetes Prevention and Treatment of Microchace Complications Real World Project"

In recent years, with the continuous development and progress of my country's socioeconomic and economy, people's lifestyles have changed significantly, and the prevalence of diabetes has increased rapidly. In order to respond and implement the strategic planning spirit of the National "Healthy China Action (2019-2030)", the standardization and homogeneous management of type 2 diabetes are promoted.

On July 21, the "Diabetes Prevention and Treatment of Microchacement of Micromiors complications" was held online on July 21, co -sponsored by the three major authoritative institutions of the China Medical Association, the Chinese Medical Association magazine, and the editorial institution of the China Diabetes Magazine Editorial Committee. Heavyweight guests and scholars in the endocrine field were invited to attend, and the project was strongly supported by Ling Pharmaceutical.

Chairman of the Endocrinology Branch of the Chinese Medical Association and Professor Zhao Jiajun, the Shandong Provincial Hospital as the chairman of this meeting, the chairman of the Chinese Medical Association Endocrinology Branch, Professor Wang Weiqing, Ruijin Hospital affiliated to Shanghai Jiaotong University, deputy Chairman of the Director, Professor Hong Tianfu of the Third Hospital of Peking University, and Zhang Xiaodong, the editorial department of the Chinese Diabetes Magazine as the host and speaker, conducted the "Diabetes Prevention and Treatment of Microvascular Complications Real World Project", abnormal blood sugar fluctuations and Jinlida intervention research content Introduction and sharing.

Professor Zhao Jiajun, the chairman of the conference, the leader of the "Diabetes Prevention and Treatment of Microchemical Micromasari", introduced in his speech that the number of patients with diabetes in my country has reached 140 million. However, the awareness rate, treatment rate, and control rate of diabetes are not ideal. Therefore, the standardized management of diabetes is very important. He hopes that through the development of "Diabetes Prevention and Treatment of Micromagiole Materia Medica Real World Project", it will continue to improve the current status of diabetes in my country, further increase the public's understanding of diabetes, increase the awareness rate, treatment rate, control rate and standard rate of diabetes, so that The benefits of polydoor patients have also contributed to the realization of healthy China.

Director Zhang Xiaodong, the editorial department of China Diabetes Magazine, introduced the content of the project as a whole. She said that "Diabetes Prevention and Treatment of Microchace Complications Real World Project" is an important branch of "Comprehensive Management Promotion Project of Diabetes Health". As a brand activity in the field of diabetic management in recent years, there are two main goals for the "Comprehensive Management Promotion Project of Diabetes Health Management". One is to improve the standardized diagnosis and treatment of endocrine doctors for diabetes health management. Improve the self -health management capabilities of patients with diabetes. Director Zhang Xiaodong hopes that related research results and typical cases of real world research can be published and displayed on journals and platforms such as the Chinese Medical Association and the Chinese Medical Association Case Library, providing more research data and reference for clinical clinics.

Liu Jian, general manager of Yiling Pharmaceutical Hospital, was invited to participate in the meeting and delivered speeches on behalf of the enterprise. He introduced that Ling Pharmaceutical has always taken "inheritance innovation and benefiting human beings" as its corporate purpose. After 30 years of development, the company has created the "five -in -one" Chinese medicine innovation conversion new conversion of theory, clinical, new drugs, experiments, and evidence -based. model. The "Construction of Traditional Chinese Medicine Poems and the Prevention of Microbial Micro Veter lesions", which was presided over by Yiling Pharmaceutical, won the first prize of national science and technology progress in 2019.

He said that Yiling Pharmaceutical is very honored to be able to carry out the "Diabetes Prevention Microchacemental Microchemical Microba True World Project" and the Chinese Medical Association Magazine, the Chinese Diabetes Magazine Editorial Committee, and experts and scholars across the country under the guidance of experts and scholars across the country. Related activities. It is hoped that through the continuous advancement of the project, it will provide more evidence -based medical evidence to the clinical clinical and contribute to the healthy China 2030.

In the academic exchanges of the conference, Professor Wang Weiqing interpreted the series of research results of Jinlida granules. She introduced the clinical study of the impact of blood sugar fluctuations of type 2 diabetes patients with academicians of Academician Jia Weiping, the sixth People's Hospital affiliated to Shanghai Jiaotong University. Blood glucose, postprandial blood glucose) and Chinese medicine syndrome scores. Compared with the control group, the blood glucose level standard deviation of the Patients of the Jinlida particles decreased significantly after treatment (-0.39VS. 0.11, P <0.01), and the time (TIR) ​​within the scope of the blood glucose target improved significantly (23.21% after treatment (23.21%) vs.2.24%, P <0.01), and the Tir of the Patients of the Jinlida particle group increased from 55%before treatment to 79%after treatment. It shows that Jinlida particles can improve the blood glucose control and blood sugar fluctuations of patients with type 2 diabetes. Professor Wang Weiqing said that through today's project launch, experts will improve the clinical evidence of the real world of microvascular complications in patients with blood sugar and delaying type 2 diabetes in patients with type 2 diabetes, providing more evidence -based medical evidence for diabetes treatment. For doctors with more sufficient treatment options clinically.

Conference expert consultant meeting, Professor Liu Ming of Tianjin Medical University General Hospital, Professor Chen Qiu, affiliated to Chengdu University of Traditional Chinese Medicine, Professor Shan Zhongyan, First Affiliated Hospital of China Medical University, Professor Xu Chun, the Third Medical Center of the General Hospital of the PLA More than 30 experts as hosts and discussion guests, for the two topics of the new blood glucose target range (TIR) ​​and diabetes in the "Chinese Type 2 Diabetes Guide (2020 Edition)" Essence

It is understood that the "Comprehensive Management of Diabetes Health Management Promotion Project" was officially launched nationwide in November 2021.The content of this project is very rich, including the guide for the lecturer training meeting of the guide, the "Lida Cup" China Diabetes Clinical Case Contest, the co -construction of diabetic disciplines, grassroots assistance and education of diabetic patients.The "Diabetes Prevention Microchacement Micromiors complications real world project" launched this time is guided by clinical value and premise of clinical implementation. Based on people's experience, combined with real world research design ideas, internationally recognized evaluation methods and internationally recognized evaluation methods and internationally recognized evaluation methods andThe means, which opened a study that provides more evidence -based medical evidence for the clinic.The project will better help drugs are widely prescribed and applied in clinical and patient treatment.Serve clinical practice and benefit patients.

- END -